Label-free quantitative proteomic analysis reveals strong involvement of complement alternative and terminal pathways in human glomerular sclerotic lesions

Journal of Proteomics

Volumn 123, Issue , 2015, Pages 89-100

  Zhang, Ying ^a,b   Xu, Bo ^a   Kinoshita, Naohiko ^a   Yoshida, Yutaka ^a   Tasaki, Masayuki ^a   Fujinaka, Hidehiko ^a,c   Magdeldin, Sameh ^a,d   Yaoita, Eishin ^a   Yamamoto, Tadashi ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c National Hospital Organization Niigata National Hospital   (Japan)

^d Suez Canal University   (Egypt)

Author keywords

Complement alternative and terminal pathways; Glomerular sclerosis; Mass spectrometry based quantitative proteomics; Normalized spectral index

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; TRANSFORMING GROWTH FACTOR BETA1; TRYPSIN; VITRONECTIN; COMPLEMENT; PROTEOME;

ACTIN FILAMENT; ADULT; AGED; ANTIBODY LABELING; ARTICLE; BIOINFORMATICS; CELL MEMBRANE; CELL NUCLEUS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DISEASE COURSE; ENDOCYTOSIS; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LASER MICRODISSECTION; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TISSUE SECTION; BIOLOGY; BLADDER TUMOR; CARCINOMA; COMPLEMENT ALTERNATIVE PATHWAY; FOCAL GLOMERULOSCLEROSIS; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; UROTHELIUM;

AGED; CARCINOMA; CARCINOMA, RENAL CELL; CHROMATOGRAPHY, LIQUID; COMPLEMENT FACTOR B; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; COMPUTATIONAL BIOLOGY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEOME; TANDEM MASS SPECTROMETRY; TRANSFORMING GROWTH FACTOR BETA1; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84928165151     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.03.024     Document Type: Article

References (40)

1. Barisoni L. Podocyte biology in segmental sclerosis and progressive glomerular injury. Adv Chronic Kidney Dis Mar 2012, 19(2):76-83.
2. D'Agati V.D. Pathobiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens May 2012, 21(3):243-250.
3. Cameron J.S. Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant Aug 2003, 18(Suppl. 6):vi45-vi51.
4. Wyatt C.M., Meliambro K., Klotman P.E. Recent progress in HIV-associated nephropathy. Annu Rev Med 2012, 63:147-159.
5. Raparia K., Usman I., Kanwar Y.S. Renal morphologic lesions reminiscent of diabetic nephropathy. Arch Pathol Lab Med Mar 2013, 137(3):351-359.
6. Griffin K.A., Bidani A.K. Hypertensive renal damage: insights from animal models and clinical relevance. Curr Hypertens Rep Apr 2004, 6(2):145-153.
7. Xu B.J., Shyr Y., Liang X., Ma L.J., Donnert E.M., Roberts J.D., et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol Oct 2005, 16(10):2967-2975.
8. Gbadegesin R1., Lavin P., Foreman J., Winn M. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. Pediatr Nephrol Jul 2011, 26(7):1001-1015.
9. Papeta N1., Kiryluk K., Patel A., Sterken R., Kacak N., Snyder H.J., et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; Nov, 22(11):1991-1996.
10. Nakatani S., Wei M., Ishimura E., Kakehashi A., Mori K., Nishizawa Y., et al. Proteome analysis of laser microdissected glomeruli from formalin-fixed paraffin-embedded kidneys of autopsies of diabetic patients: nephronectin is associated with the development of diabetic glomerulosclerosis. Nephrol Dial Transplant May 2012, 27(5):1889-1897.
11. Satoskar A.A., Shapiro J.P., Bott C.N., Song H., Nadasdy G.M., Brodsky S.V., et al. Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol May 2012, 25(5):709-721.
12. Miyamoto M., Yoshida Y., Taguchi I., Nagasaka Y., Tasaki M., Zhang Y., et al. In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein prefractionation in combination with liquid chromatography-tandem mass spectrometry. J Proteome Res Sep 2007, 6(9):3680-3690.
13. Griffin N.M., Yu J., Long F., Oh P., Shore S., Li Y., et al. Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol Jan 2010, 28(1):83-89.
14. Xu B., Zhang Y., Zhao Z., Yoshida Y., Magdeldin S., Fujinaka H., et al. Usage of electrostatic eliminator reduces human keratin contamination significantly in gel-based proteomics analysis. J Proteomics Jun 2011, 74(7):1022-1029.
15. Zhang Y., Xu B., Kinoshita N., Yoshida Y., Tasaki M., Fujinaka H., et al. Datasets from label-free quantitative proteomic analysis of human glomeruli with sclerotic lesions 2015, [Data in Brief submitted].
16. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29.
17. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
18. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:P3.
19. Garcia C.D., Bittencourt V.B., Tumelero A., Antonello J.S., Malheiros D., Garcia V.D. Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis. Transplant Proc Jul-Aug 2006, 38(6):1904-1905.
20. McCarthy E.T., Sharma M., Savin V.J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol Nov 2010, 5(11):2115-2121.
21. Lea S.M., Johnson S. Putting the structure into complement. Immunobiology Nov 2012, 217(11):1117-1121.
22. Yang K., DeAngelis R.A., Reed J.E., Ricklin D., Lambris J.D. Complement in action: an analysis of patent trends from 1976 through 2011. Adv Exp Med Biol 2013, 735:301-313.
23. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol Oct 2009, 9(10):729-740.
24. Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol Apr 2005, 16(4):1035-1050.
25. Servais A., Noël L.H., Frémeaux-Bacchi V., Lesavre P. C3 glomerulopathy. Immunobiology Nov 2012, 217(11):1117-1121.
26. Sethi S., Gamez J.D., Vrana J.A., Theis J.D., Bergen H.R., Zipfel P.F., et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int May 2009, 75(9):952-960.
27. Hindmarsh E.J., Marks R.M. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol Jun 1998, 160(12):6128-6136.
28. Sahu A., Kozel T.R., Pangburn M.K. Specificity of the thioester containing reactive site of human C3 and its significance to complement activation. Biochem J 1994, 302-429.
29. Hughes J1., Nangaku M., Alpers C.E., Shankland S.J., Couser W.G., Johnson R.J. C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol Renal Physiol May 2000, 278(5):F747-F757.
30. Sato T., Van Dixhoorn M.G., Prins F.A., Mooney A., Verhagen N., Muizert Y., et al. The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. J Am Soc Nephrol 1999, 10:1242-1252.
31. Lee H.S. Pathogenic role of TGF-β in the progression of podocyte diseases. Histol Histopathol Jan 2011, 26(1):107-116.
32. Fischer E., Appay M.D., Cook J., Kazatchkine M.D. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol 1986, 136(4):1373-1377.
33. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int Nov 1998, 54(5):1419-1428.
34. Choi N.H., Nakano Y., Tobe T., Mazda T., Tomita M. Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol 1990, 2:413-417.
35. Nauta A.J., Daha M.R., Tijsma O., van de Water B., Tedesco F., Roos A. The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol 2002, 32:783-792.
36. Lindberg S., Pedersen S.H., Mogelvang R., Galatius S., Flyvbjerg A., Jensen J.S., et al. Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am Heart J Nov 2012, 164(5):786-792.
37. Corallini F., Bossi F., Gonelli A., Tripodo C., Castellino G., Mollnes T.E., et al. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology (Oxford) Mar 2009, 48(3):293-298.
38. Sampogna R.V., Al-Awqati Q. Taking a bite: endocytosis in the maintenance of the slit diaphragm. J Clin Invest 2012, 122(12):4330-4333.
39. Soda K., Balkin D.M., Ferguson S.M., Paradise S., Milosevic I., Giovedi S., et al. Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. J Clin Invest 2012, 122(12):4401-4411.
40. Loebrich S. The role of F-actin in modulating Clathrin-mediated endocytosis: lessons from neurons in health and neuropsychiatric disorder. Commun Integr Biol Apr 2014, 3(7):e28740.